Analysts/Institutional Investor Meet/Con. Call Updates

Concord Biotech Limited has informed the Exchange about Presentation of unaudited Standalone and Consolidated Financial Results for the first Quarter ended on June 30, 2026. The company witnessed broad-based growth across all product categories, with exports growing by ~46% for Q1FY27 (Y-o-Y). The company received USFDA approval for its ANDA for Mycophenolate Mofetil & Tofacitinib Tablets and started commercial operations & sales at Stellon Biotech. The company also received a Silver medal from EcoVadis placing Concord among the top 15% companies assessed globally.